CiVi Biopharma
Carole Nuechterlein has headed the Roche Venture Fund since 2001. She joined Roche from SangStat where she was General Counsel from 1998 to 2001. Prior to SangStat, Ms. Nuechterlein worked in the pharmaceutical/biotech industry as an attorney for ten years.
In addition to serving on CiVi Biopharma’s Board of Directors, Ms. Nuechterlein currently serves as a director at Aligos Therapeutics, Arch Oncology, Entrada Therapeutics, Maculogix, Millendo Therapeutics, Mission Therapeutics, Second Genome and Vivet Therapeutics. She was formerly a director at Allakos and AveXis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.